2023 World Conference on Lung Cancer (Posters)-EP12.01. Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE)

EP12.01. Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE) - PDF(Slides)

Back to course

Pdf Summary

The study titled "Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE)" aimed to evaluate the efficacy and safety of the third-generation EGFR-TKI aumolertinib as a first-line treatment for patients with EGFR-mutant adenosquamous carcinoma (ASC) of the lungs. ASC is a relatively uncommon malignancy that consists of adenocarcinoma and squamous cell carcinoma components. The primary treatment for ASC is chemotherapy, but patient prognosis remains poor. Previous studies have shown that ASCs are associated with EGFR mutations in Asian populations.<br /><br />The study enrolled 12 patients with EGFR-mutant ASC and administered aumolertinib as the treatment. The results showed that seven out of 12 patients achieved a partial response, resulting in an objective response rate of 58.3%. Disease control rate was 83.3%. One patient with baseline CNS metastases achieved an intracranial complete response. The median progression-free survival was 6.2 months, and the median overall survival was not reached during the study period.<br /><br />Treatment-related adverse events were reported in 63.6% of patients, with the most common being anemia and increased aspartate aminotransferase. Overall, aumolertinib demonstrated promising antitumor activity with a manageable toxicity profile in patients with EGFR-mutant ASC.<br /><br />The study concludes that this is the first prospective study to show the efficacy of aumolertinib in EGFR-mutant ASC, highlighting its potential as a treatment option for this rare subtype of lung cancer. These findings support the use of third-generation EGFR-TKIs in the treatment of EGFR-mutant ASC.

Asset Subtitle

Gen Lin

Meta Tag

Speaker Gen Lin

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Aumolertinib

EGFR-mutant

Pulmonary Adenosquamous Carcinoma

ARISE

first-line treatment

efficacy

safety

adenosquamous carcinoma

chemotherapy

rare subtype of lung cancer